Literature DB >> 9690408

Identification of tryptophan hydroxylase as an intestinal autoantigen.

O Ekwall1, H Hedstrand, L Grimelius, J Haavik, J Perheentupa, J Gustafsson, E Husebye, O Kämpe, F Rorsman.   

Abstract

BACKGROUND: Autoimmune polyendocrine syndrome type 1 (APS1) is an autosomal recessive disorder with both endocrine and non-endocrine features. Periodic gastrointestinal dysfunction occurs in 25-30% of APS1 patients. We aimed to identify an intestinal autoantigen.
METHODS: A human duodenal cDNA library was immunoscreened with serum samples from APS1 patients. A positive clone was identified and used for in-vitro transcription and translation, followed by immunoprecipitation with serum samples from 80 APS1 patients from Norway, Finland, and Sweden. Sections of normal and APS1-affected small intestine were immunostained with serum from APS1 patients and specific antibodies. An enzyme-inhibition assay was used to characterise the autoantibodies.
FINDINGS: We isolated a cDNA clone coding for tryptophan hydroxylase. 48% (38/80) of APS1 patients had antibodies to tryptophan hydroxylase, whereas no reactivity to this antigen was detected in patients with other autoimmune diseases (n=372) or healthy blood donors (n=70). 89% (17/19) of APS1 patients with gastrointestinal dysfunction were positive for antibodies to tryptophan hydroxylase, compared with 34% (21/61) of patients with no gastrointestinal dysfunction (p<0.0001). Serum from antibody-positive APS1 patients specifically immunostained tryptophan-hydroxylase-containing enterochromaffin cells in normal duodenal mucosa. No serotonin-containing cells were seen in duodenal biopsy samples from APS1 patients. Serum from antibody-positive APS1 patients almost completely inhibited activity of tryptophan hydroxylase.
INTERPRETATION: Tryptophan hydroxylase is an endogenous intestinal autoantigen in APS1, and there is an association between antibodies to the antigen and gastrointestinal dysfunction. Analysis of antibodies to tryptophan hydroxylase may be a valuable diagnostic tool to predict and monitor gastrointestinal dysfunction in APS1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690408     DOI: 10.1016/S0140-6736(97)11050-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  45 in total

Review 1.  Autoimmune polyglandular syndrome type 1.

Authors:  P Obermayer-Straub; C P Strassburg; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity.

Authors:  P Peterson; J Pitkänen; N Sillanpää; K Krohn
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 3.  Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Gregory M Constantine; Michail S Lionakis
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

4.  Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1.

Authors:  Sophie Bensing; Sergueï O Fetissov; Jan Mulder; Jaakko Perheentupa; Jan Gustafsson; Eystein S Husebye; Mikael Oscarson; Olov Ekwall; Patricia A Crock; Tomas Hökfelt; Anna-Lena Hulting; Olle Kämpe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

5.  Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Elise M N Ferre; Stacey R Rose; Sergio D Rosenzweig; Peter D Burbelo; Kimberly R Romito; Julie E Niemela; Lindsey B Rosen; Timothy J Break; Wenjuan Gu; Sally Hunsberger; Sarah K Browne; Amy P Hsu; Shakuntala Rampertaap; Muthulekha Swamydas; Amanda L Collar; Heidi H Kong; Chyi-Chia Richard Lee; David Chascsa; Thomas Simcox; Angela Pham; Anamaria Bondici; Mukil Natarajan; Joseph Monsale; David E Kleiner; Martha Quezado; Ilias Alevizos; Niki M Moutsopoulos; Lynne Yockey; Cathleen Frein; Ariane Soldatos; Katherine R Calvo; Jennifer Adjemian; Morgan N Similuk; David M Lang; Kelly D Stone; Gulbu Uzel; Jeffrey B Kopp; Rachel J Bishop; Steven M Holland; Kenneth N Olivier; Thomas A Fleisher; Theo Heller; Karen K Winer; Michail S Lionakis
Journal:  JCI Insight       Date:  2016-08-18

Review 6.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Kai Kisand; Pärt Peterson
Journal:  J Clin Immunol       Date:  2015-07-05       Impact factor: 8.317

7.  Autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy in Calabria: clinical, immunological and genetic patterns.

Authors:  C Betterle; L Ghizzoni; A Cassio; F Baronio; S Cervato; S Garelli; E Barbi; G Tonini
Journal:  J Endocrinol Invest       Date:  2011-11-21       Impact factor: 4.256

8.  Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1.

Authors:  E Helen Kemp; Nikos G Gavalas; Kai J E Krohn; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 9.  Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?

Authors:  C Betterle; F Lazzarotto; F Presotto
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers.

Authors:  Filippo De Luca; Mariella Valenzise; Rita Alaggio; Teresa Arrigo; Giuseppe Crisafulli; Giuseppina Salzano; Sara Cervato; Barbara Mariniello; Francesca Lazzarotto; Corrado Betterle
Journal:  Eur J Pediatr       Date:  2008-02-15       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.